Treatments

*May 2022* Key Points NSCLCs harboring oncogenic EGFR mutations or ALK rearrangements can be effectively treated with EGFR and ALK TKIs respectively. The third-generation TKI osimertinib and the ALK TKI lorlatinib are currently the most advanced and effective clinically approved agents in their respective NSCLC subsets; both agents are highly…

*May 2022* Dr. Upal Basu Roy from the LUNGevity Foundation conducts discussions with Drs. Christine Lovly and Helena Yu, along with EGFR Resisters co-founders Ivy Elkins and Jill Feldman. Both Lovely and Yu received research awards from the EGFR Resisters and provide updates on their projects in this video. Dr.…

*April 2022* Ravi Salgia, MD, medical oncologist, professor, and chair, Department of Medical Oncology & Therapeutics Research, and Arthur & Rosalie Kaplan chair in Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell…

*April 2022* Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing. Read the transcript and/or watch the video here.

*April 2022* Lung cancer remains the leading cause of cancer-related deaths in the U.S. Lung cancer in non-smokers is more common than many people realize. In fact, lung cancer in never-smokers is now considered the 6th most common cause of cancer deaths in the United States. Each year lung cancer…

*April 2022* Note: Current guidelines state that molecular testing should be conducted at the time of initial diagnosis as well as tumor progression on targeted therapies. Meghan J. Mooradian, MD: I think an important question that many clinicians are faced with now is whether to use blood-based assays, tissue-based assays,…

*June 2021* Note: Most research in resistance has been studied in isolation, not accounting for the complexity tumor heterogeneity and the patient heterogeneity. This model was presented at one of the plenary sessions, considers the complex pharmacokinetics and variability of drug concentration in patients, specifically the change in concentrations of multiple…

*April 2022* Drug-tolerant “dormant” cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we performed real-time monitoring of the cell cycle dynamics during the…

*March 2022* Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn't Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.

Cancer that has spread from a solid tumor to the membranes lining the brain and spinal cord (leptomeninges) is called “leptomeningeal metastasis.” Cerebrospinal fluid (CSF) is located between the leptomeninges, in a place called the “intrathecal space.” Cancer cells within the CSF rely on iron for growth and survival. Researchers…